Business

Metis TechBio plans A-share listing

By Li Jing | chinadaily.com.cn

Updated: 2026-11-20 11:03

Share - WeChat

Metis TechBio Co Ltd, a Beijing-based biotechnology company specializing in drug delivery, has begun preparations for a potential A-share listing on the Chinese mainland, about six months after making its Hong Kong debut.

In a filing to the Hong Kong Stock Exchange on Wednesday, the company said its board had approved preparatory work for issuing renminbi-denominated ordinary shares and appointed an institution to provide pre-listing guidance.

If completed, the proposed listing would allow Metis to tap both the mainland and Hong Kong capital markets, broadening its fundraising channels and investor base. The company gave no fundraising target, exchange or timetable, and said the plan remains subject to shareholder and regulatory approvals.

Founded in 2020, Metis uses artificial intelligence to develop drug delivery technologies, including lipid nanoparticles designed to transport medicines to specific tissues and cells. Its NanoForge platform combines computational modeling with laboratory testing to develop delivery systems.

The company made its Hong Kong trading debut on May 13, offering about 201.2 million shares at HK$10.50 each and raising approximately HK$2.11 billion ($271 million) in gross proceeds before any over-allotment.

Metis reported revenue of 154.3 million yuan ($21.7 million) in the first half of 2026, up from 1.1 million yuan a year earlier, mainly driven by research collaborations and licensing activities. Its net loss attributable to shareholders stood at 153.2 million yuan.

The company reported financial resources totaling 3.03 billion yuan at the end of June, including cash, deposits and financial assets.

In October, Metis announced a collaboration with US pharmaceutical company Eli Lilly to develop tissue-specific lipid nanoparticle delivery technology.

Under the agreement, Metis is set to receive an upfront payment in the low double-digit millions of dollars and could earn up to approximately $1.1 billion in additional payments tied to development and commercial milestones.

Copyright 1994 -

Registration Number: 130349

Mobile